Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients

Fig. 3

Overall survival (OS) after cabazitaxel treatment. a OS in the all-patient cohort (median survival 16.3 months, 95% CI 19.7–30.9). b OS in the patients with the high initial CBZ dose (high-dose) group (median survival 30.9 months, 95% CI 11.8–47.4) and with the low initial CBZ dose (low-dose) group (median survival 10.2 months, 95% CI 8.6–20). P = 0.020 by log-rank test

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us